Application Note: VEGF-165 Recombinant Protein has been tested by SDS-PAGE and is suitable as a control for polyclonal or monoclonal anti-VEGF-165 in immunological assays.
Concentration Value: 0.1 mg/mL
General Disclaimer Note: This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
Other Performance Data: Biological Activity: Human recombinant VEGF-165 is fully biologically active when compared to standards. The ED50, as determined by the dose dependent induction of HUVEC proliferation, is 3.1-4.6 ng/ml.Endotoxin Level: Measured by LAL is <0.01ng/µg or <0.1EU/µg.
Physical State: Lyophilized
Purity and Specificity: Purity was determined to be greater than 95% as determined by analysis by RP-HPLC and by reducing and non-reducing SDS-PAGE against known standard.
Background: Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating vasolidation via nitric oxide-dependent pathways. Alternative splicing of the mRNA for VEGF-A results in several isoforms of the protein being produced. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent.In contrast to other factors mitogenic for endothelial cells such as FGF-1, FGF-2 and PDGF, VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF. Recombinant Human VEGF produced in E.coli is a double, non-glycosylated, polypeptide chain containing 165 amino acids and having a molecular mass of 38231 Daltons.
Low Endotoxin: Yes
Other: User Optimized
English
Deutsch
